Abstract
Objective To evaluate the clinical efficacy and safty of combined treatment telmisartan plus simvastatin on early diabetic nephropathy. Methods 46 patients with early diabetic nephropathy were randomly divided into two groups. Control group ( n = 23 ) received regular insulin therapy, captopril l0mg tid. Study group received telmisartan 80mg qd plus simvastatin 20mg qd on the basis of control group therapy. All patients received 16 weeks treatment. The clinical parameters were measured before and after therapy. Results After 16 weeks treatment,the urine MAU in both study group and control group were significantly decreased( all P <0. 01 ) ,however,the urine MAU in telmisartan plus simvastatin combination group decreased significantly than control group( P < 0. 01 ). Improvement of lipid level in the study group better than the control group( P <0. 01 ). Kidney function,fasting blood glucose levels and HbAlc had no significant changes before and after treatment. Conclusion Telmisartan plus simvastatin combined treatment was better than the traditional therapy,which can delay the development of early diabetic nephropathy. Key words: Diabetic nephropathy; Telmisartan; Simvastatin
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have